Zoledronic acid + Placebo

Phase 2/3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Beta-Thalassemia

Conditions

Beta-Thalassemia, Bone Marrow Transplantation

Trial Timeline

Nov 1, 2009 → Dec 1, 2011

NCT ID

NCT01016093

About Zoledronic acid + Placebo

Zoledronic acid + Placebo is a phase 2/3 stage product being developed by Novartis for Beta-Thalassemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01016093. Target conditions include Beta-Thalassemia, Bone Marrow Transplantation.

What happened to similar drugs?

2 of 7 similar drugs in Beta-Thalassemia were approved

Approved (2) Terminated (0) Active (5)

✅DeferasiroxNovartisApproved

✅ICL670NovartisApproved

🔄deferasiroxNovartisPhase 3

🔄ICL670 + deferoxamineNovartisPhase 3

🔄CTX001Vertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01788176	Phase 2	UNKNOWN	Dec 1, 2013	Dec 1, 2016	Complex Regional Pain Syndromes
NCT01702415	Approved	Withdrawn	Oct 1, 2013	Dec 1, 2015	Cystic Fibrosis
NCT01166178	Phase 3	Terminated	Oct 1, 2010	Jun 1, 2012	Osteoporosis
NCT00844480	Phase 2	Terminated	Mar 1, 2010	Jan 1, 2016	Bone Loss
NCT01016093	Phase 2/3	UNKNOWN	Nov 1, 2009	Dec 1, 2011	Beta-Thalassemia
NCT00781261	Phase 2	UNKNOWN	Aug 1, 2009	Dec 1, 2013	Osteonecrosis
NCT00799266	Phase 3	Completed	Dec 4, 2008	Mar 5, 2018	Osteoporosis
NCT00333229	Approved	Terminated	Mar 1, 2006	Dec 1, 2013	Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
NCT00320710	Phase 3	Completed	Feb 1, 2006	Jul 1, 2013	Breast Cancer
NCT00375505	Phase 3	Completed	Oct 1, 2005	May 1, 2014	Breast Cancer
NCT00145327	Phase 3	Completed	May 1, 2005	Nov 1, 2009	Osteoporosis
NCT00132808	Phase 3	Completed	Jul 1, 2004	Feb 1, 2008	Osteopenia

Competing Products

18 competing products in Beta-Thalassemia

See all competitors

Product	Company	Stage	Hype Score
ACE-536	Merck	Phase 2	42
Deferasirox	Novartis	Approved	43
deferasirox	Novartis	Phase 3	40
ICL670 + deferoxamine	Novartis	Phase 3	40
Deferasirox	Novartis	Phase 2	35
Deferasirox	Novartis	Phase 2	35
ICL670	Novartis	Approved	43
Bitopertin	Roche	Phase 2	35
Luspatercept + Placebo	Bristol Myers Squibb	Phase 2	39
CTX001	Vertex Pharmaceuticals	Phase 3	44
CTX001	Vertex Pharmaceuticals	Phase 3	47
CTX001	Vertex Pharmaceuticals	Phase 2/3	38
CTX001	Vertex Pharmaceuticals	Phase 3	47
Mozobil + Mozobil + Mozobil	Sanofi	Pre-clinical	26
Deferitrin (GT56-252) + desferoxamine (DFO)	Sanofi	Phase 1/2	32
REGN7999 + Placebo	Regeneron Pharmaceuticals	Phase 2	42
VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + Placebo	LabCorp	Phase 2	24
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + Placebo	LabCorp	Phase 2	32